Rare Rheumatology News

Advertisement

Spotlight On

Activated PI3K Delta Syndrome (APDS)

Activated PI3K Delta Syndrome (APDS) is a rare, genetic primary immunodeficiency

Prevalence

< 1 / 1,000,000

Prevalence

< 331

US Estimated

< 514

Europe Estimated

Age of Onset

ICD-10

D81.8

Inheritance

Autosomal dominant

Caregiver Corner

Access the latest tools and resources for patients and caregivers living with APDS

Rare View

Activated PI3K delta syndrome, known as APDS (previously known as PASLI* Disease) is a rare primary immunodeficiency, first discovered in 2013. APDS is caused by genetic variants in either one of two genes known as PIK3CD or PIK3R1, which encode proteins that are vital to the normal development and function of immune cells. Signs and symptoms of APDS start in childhood, and patients are vulnerable to repeat infections and immune dysregulation such as lymphadenopathy, splenomegaly, autoimmune cytopenias, and even lymphoma.

5 Facts you should know

FACT

1

APDS a Primary Immunodeficiency, was only characterized in 2013 though shares many features of other immune disorders, which means APDS patients may have been previously misdiagnosed with other conditions.

FACT

2

Signs and symptoms of APDS start in childhood, and patients are vulnerable to repeat infections and immune dysregulation such as sinusitis, severe respiratory tract infections, recurrent herpes or EBV/CMV, lymphadenopathy and autoimmune cytopenias.

FACT

3

Immunologists may mistake APDS for combined immunodeficiency (CID) or common variable immune deficiency (CVID) or hyper IgM syndrome (HIGM).

FACT

4

Genetic testing is the only way to definitively diagnose APDS and other primary immunodeficiencies.

FACT

5

Management of APDS is symptomatic – antibiotics, antivirals or IVIG may be used to treat or prevent recurrent infections immunodeficiencies.

Activated PI3K delta syndrome (APDS)

Activated PI3K delta syndrome (APDS) is also known as

PASLI disease, p110 delta-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency

What’s your rare IQ?

Activated PI3K Delta Syndrome (APDS) is one of more than 400 defined Primary Immunodeficiencies (PIs). Which of the following is not a Primary Immunodeficiency?

Common Signs & Symptoms

Bronchiectasis

Permanent enlargement of the airways of the lungs

Decreased circulating IgG2 level

Decreased proportion of class-switched memory B cells

Decreased specific pneumococcal antibody level

Increased circulating IgM level

Increased proportion of transitional B cells

Lymphadenopathy

Swollen lymph nodes

Recurrent ear infections

Frequent ear infections

† All About APDS https://allaboutapds.com

Caregiver Corner
Tools and resources for your patients living with APDS

Comprehensive Care Centers

If you or someone you care for suspects they may have APDS, or you’ve been given an APDS diagnosis, it’s important to find a physician who is familiar with diagnosing and managing patients with APDS. This tool features experts who can support patients through diagnosis, disease management and genetic testing. Click below to find a physician in your area.

Featured Resources

Understanding The APDS Patient Experience Video - This video highlights the variety and severity of symptoms that each person with APDS may experience and the importance of genetic testing.
APDS – Mechanism Of Disease Video - What is happening in my body? Learn how APDS affects the body
An overview of Activated PI3K Delta Syndrome (APDS) and primary immunodeficiencies

Help your patients learn about APDS and primary immunodeficiencies. Get years of knowledge and experience condensed into a simple report.

Valued sources of information

Impact of the disease on daily life

Seizure triggers and control

Symptom history

Experience with various treatments

Challenges, frustrations, and suppport needs

Other resources

Click the drop-down to see info on Patient Advocacy Groups and a Glossary of common terms

  • Immune Deficiency Foundation (IDF) IDF is a national nonprofit organization dedicated to improving the diagnosis, treatment, and quality of life of individuals affected by primary immunodeficiency diseases through advocacy, education, and research.
  • Jeffrey Modell Foundation (JMF) - JMF is a global nonprofit organization dedicated to early diagnosis, meaningful treatments, and ultimately cures for primary immunodeficiency diseases. The foundation provides support, education, and advocacy for patients and families affected by these conditions.
  • Foundation for Primary Immunodeficiency Diseases (FPID) - Established in the United States to support the education, early diagnosis, genetic counseling, therapy, and research of PID in both India and the United States.
  • Advocacy & Awareness for Immune Disorders Association (AAIDA) - Dedicated to patients living with immune dysregulation and overlapping conditions with a focus on advocacy campaigns, educational initiatives, and research opportunities. AAIDA also provides patients and healthcare providers assistance with insurance denials and medication assistance programs available across the United States.
  • American Partnership for Eosinophilic Disorders (APFED) - While not exclusively focused on primary immunodeficiencies, APFED provides support, education, and advocacy for individuals with eosinophilic disorders, which can sometimes occur alongside primary immunodeficiency conditions.
  • Activated PI3K Delta Syndrome (APDS): A rare primary immunodeficiency that affects approximately 1 to 2 people per million. It occurs when there are variations to the PIK3CD or PIK3R1 genes.
  • Primary Immunodeficiency (PID): A group of disorders characterized by defects in the immune system present from birth, leading to increased susceptibility to infections.
  • Innate Immunity: The first line of defense against pathogens, involving physical barriers (eg., skin), cellular responses (eg., macrophages, neutrophils), and soluble factors (eg., complement proteins).
  • Adaptive Immunity: The immune response mediated by lymphocytes (T and B cells) that specifically targets pathogens and develops memory for future encounters.
  • T-Cell Deficiency: A primary immunodeficiency characterized by defects in T lymphocytes, leading to impaired cell-mediated immunity and increased susceptibility to viral, fungal, and certain bacterial infections.
  • B-Cell Deficiency: A primary immunodeficiency characterized by defects in B lymphocytes, leading to impaired humoral immunity and increased susceptibility to bacterial infections, particularly encapsulated bacteria.
  • Combined Immunodeficiency: A primary immunodeficiency characterized by defects affecting both T and B lymphocytes, leading to severe immunodeficiency and susceptibility to a wide range of infections.
  • Severe Combined Immunodeficiency (SCID): A rare and severe form of combined immunodeficiency characterized by profound defects in both T and B lymphocytes, often resulting in life-threatening infections within the first few months of life.
  • Antibody Deficiency: A primary immunodeficiency characterized by defects in antibody production, leading to impaired humoral immunity and increased susceptibility to bacterial infections, especially extracellular pathogens.
  • Common Variable Immunodeficiency (CVID): A primary immunodeficiency characterized by low levels of serum immunoglobulins (particularly IgG and IgA), leading to recurrent bacterial infections, autoimmune disorders, and an increased risk of malignancy.
  • Complement Deficiency: A primary immunodeficiency characterized by defects in components of the complement system, leading to impaired opsonization, chemotaxis, and lysis of pathogens, resulting in increased susceptibility to bacterial infections, particularly Neisseria species.
  • Phagocytic Defects: A primary immunodeficiency characterized by defects in phagocytes (eg., neutrophils, macrophages), leading to impaired clearance of pathogens and increased susceptibility to bacterial and fungal infections.
  • Hyper IgM Syndrome: A primary immunodeficiency characterized by defective class switching of immunoglobulins, resulting in low levels of IgG and IgA but normal or elevated levels of IgM, leading to increased susceptibility to bacterial infections.
  • X-linked Agammaglobulinemia (XLA): A primary immunodeficiency caused by mutations in the gene encoding Bruton’s tyrosine kinase (BTK), resulting in the absence of mature B cells and low levels of immunoglobulins, leading to recurrent bacterial infections.
  • Autoimmune Lymphoproliferative Syndrome (ALPS): A primary immunodeficiency characterized by defective apoptosis of lymphocytes, leading to lymphoproliferation, autoimmune manifestations, and an increased risk of lymphoma.
  • Hematopoietic Stem Cell Transplantation (HSCT): A procedure in which hematopoietic stem cells are infused into a patient to restore bone marrow function and immune system competence often used as a treatment for severe primary immunodeficiencies.